Ashley Gallagher

6 days ago | drugtopics.com | Ashley Gallagher

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria (CSU) who are symptomatic despite histamine-1 antihistamine treatment.1 “CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living,” Alyssa Johnsen, MD, PhD, global therapeutic head of immunology and oncology development at Sanofi, said in a news release.1 “This FDA approval provides a new treatment option to help...

6 days ago | drugtopics.com | Ashley Gallagher

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to recommend a single dose of the chikungunya vaccine, recombinant (Vimkunya), for the prevention of disease caused by the chikungunya virus.

1 week ago | drugtopics.com | Ashley Gallagher

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to expand the recommended use of the respiratory syncytial virus (RSV) vaccine currently approved for adults aged 50 to 59 years who are at an increased risk of RSV-associated lower respiratory tract disease (LRTD).

1 week ago | drugtopics.com | Ashley Gallagher

The CDC Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of meningococcal groups A, B, C, W, and Y vaccine (Penmenvy) as part of the adolescent meningococcal vaccination schedule. The recommendation states that patients older than 10 years receive a single dose of Penmenvy as an alternative to separate administration of meningococcal serogroups A, C, W, and Y (MenACWY) and meningococcal serogroup B (MenB) vaccinations.

1 week ago | drugtopics.com | Ashley Gallagher

New data show icotrokinra (JNJ-2113) is efficacious and safe as a systemic therapy in both adolescents and adults, according to a phase 3 registrational study for moderate-to-severe plaque psoriasis.